Reviewing Aptose Biosciences Inc. (APTO)’s and Acer Therapeutics Inc. (NASDAQ:ACER)’s results

Aptose Biosciences Inc. (NASDAQ:APTO) and Acer Therapeutics Inc. (NASDAQ:ACER) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptose Biosciences Inc. 2 0.00 46.01M -0.77 0.00
Acer Therapeutics Inc. 3 0.00 3.46M -2.71 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Aptose Biosciences Inc. and Acer Therapeutics Inc.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Aptose Biosciences Inc. 1,995,229,835.21% -182.8% -152.7%
Acer Therapeutics Inc. 105,122,440.30% -67.4% -61.7%

Risk and Volatility

Aptose Biosciences Inc. is 61.00% more volatile than S&P 500 due to its 1.61 beta. Acer Therapeutics Inc. has a 1.48 beta and it is 48.00% more volatile than S&P 500.


The current Quick Ratio of Aptose Biosciences Inc. is 5.9 while its Current Ratio is 5.9. Meanwhile, Acer Therapeutics Inc. has a Current Ratio of 10.9 while its Quick Ratio is 10.9. Acer Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Aptose Biosciences Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Aptose Biosciences Inc. and Acer Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aptose Biosciences Inc. 0 0 1 3.00
Acer Therapeutics Inc. 0 0 0 0.00

The consensus target price of Aptose Biosciences Inc. is $6, with potential upside of 127.27%.

Institutional & Insider Ownership

The shares of both Aptose Biosciences Inc. and Acer Therapeutics Inc. are owned by institutional investors at 35.1% and 61.1% respectively. Insiders owned 20.4% of Aptose Biosciences Inc. shares. Competitively, 0.3% are Acer Therapeutics Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aptose Biosciences Inc. -6.67% -4.55% 29.23% 22.93% -12.8% 31.94%
Acer Therapeutics Inc. 2.4% -23.92% -84.35% -87.67% -84.67% -85.14%

For the past year Aptose Biosciences Inc. has 31.94% stronger performance while Acer Therapeutics Inc. has -85.14% weaker performance.


Aptose Biosciences Inc. beats on 6 of the 10 factors Acer Therapeutics Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.